-
Your selected country is
Belgium
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Analysis of CD62L on human lymphocytes. Cells from lysed whole blood were stained with BD Horizon™ V450 Mouse Anti-Human CD62L and compared to lysed whole blood stained with BD Horizon™ V450 Mouse IgG1, κ Isotype Control (clone MOPC-21, Cat. No. 560373). The isotype control is represented by a dashed line and the V450 Mouse Anti-Human CD62L by the solid line. Flow cytometry was performed on a BD LSR™ II flow cytometry system.
BD Pharmingen™ V450 Mouse Anti-Human CD62L
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- BD Horizon V450 has a maximum absorption of 406 nm and maximum emission of 450 nm. Before staining with this reagent, please confirm that your flow cytometer is capable of exciting the fluorochrome and discriminating the resulting fluorescence.
- Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
The DREG-56 monoclonal antibody specifically binds to CD62L. CD62L is a 76-95 kDa glycoprotein that is also referred to as L-selectin or LECAM-1. CD62L is expressed on neutrophils, monocytes, T- and B-lymphocyte subsets and NK cells. The DREG-56 antibody recognizes the same antigen as LAM-1, and specifically inhibits >90% of binding of human lymphocytes to high endothelial venules (HEV) in frozen sections of peripheral, but not mucosal lymphoid tissue. It thus defines L-selectin as a human lymphocyte homing receptor for peripheral lymph node HEV.
The antibody is conjugated to BD Horizon™ V450, which has been developed for use in multicolor flow cytometry experiments and is available exclusively from BD Biosciences. It is excited by the Violet laser Ex max of 406 nm and has an Em Max at 450 nm. Conjugates with BD Horizon™ V450 can be used in place of Pacific Blue™ conjugates.
Development References (3)
-
Kishimoto TK, Jutila MA, Butcher EC. Identification of a human peripheral lymph node homing receptor: a rapidly down-regulated adhesion molecule. Proc Natl Acad Sci U S A. 1990; 87(6):2244-2248. (Biology). View Reference
-
Kishimoto TK, Warnock RA, Jutila MA, et al. Antibodies against human neutrophil LECAM-1 (LAM-1/Leu-8/DREG-56 antigen) and endothelial cell ELAM-1 inhibit a common CD18-independent adhesion pathway in vitro. Blood. 1991; 78(3):805-811. (Biology). View Reference
-
Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.